Lund, Sweden, 12:00 pm CET, 30 December 2019 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During December, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased with 60,000 due to the exercise of warrants. As of 31 December 2019, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to 52,521,342 shares, of which 52,016,342 are ordinary shares with one vote per share and 505,000 are series C shares with one–tenth of a vote per share. The number of votes in the company amounts to 52,066,842 votes.
BONESUPPORT™ (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio–ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2021. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
+46 (0) 708 76 87 87
The information in the press release is such that BONESUPPORT HOLDING AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 12:00 pm CET on 30 December 2019.